New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 5, 2012
06:14 EDTPTR, HES, AAPL, RDS.AOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Russia is close to joining the WTO, a landmark move to integrate their economy into the international trading system, but U.S. firms may be left out because of restrictions on trade, the Wall Street Journal reports...Talks to resolve U.S. and European price fixing probes into e-books are picking up as three international publishers may want to settle, while Apple (AAPL) and others resist, sources say, the Wall Street Journal reports...REUTERS: PetroChina (PTR) is in talks with Royal Dutch Shell (RDS.A) and Hess (HES) to explore shale oil in Santanghu Basin in China's northwestern Xinjiang region, Reuters reports...BLOOMBERG: Four Federal Reserve regional bank presidents who vote on monetary policy this year see less of a need for the Fed to spur the economy with new accommodation, Bloomberg reports...For the first time in 2012, gold traders are bearish after the Fed signaled it may refrain from more monetary stimulus and jewelers in India, the biggest bullion market, closed to protest a new tax, Bloomberg reports.
News For A;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
15:23 EDTADako announces FDA approval of new lung test for cancer patients
Subscribe for More Information
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use